RNASeq data from OMP-52M51 acute treated T-ALL PDX mice

We recently demonstrated that a human Notch1-specific neutralizing antibody (OMP-52M51) was very effective in T-ALL patient derived xenografts (PDX) bearing NOTCH1/FBW7 mutations. To evaluate the transcriptomic downstream effects of anti-NOTCH1 therapy, we perform RNA-Seq analysis in leukemia cells derived from PDTALL46 PDX mice after an acute treatment with control Ab or OMP-52M51. Cells from spleens of control (Ctrl Ab) or OMP-52M51 antiboby acute treated mice were recovered for RNA extraction and RNASEq analysis. Each sample derived from a different mouse (4 mice/group).

我们近期研究表明，人源Notch1特异性中和抗体（OMP-52M51）对携带NOTCH1/FBW7突变的T细胞急性淋巴细胞白血病（T-cell Acute Lymphoblastic Leukemia, T-ALL）患者来源异种移植模型（Patient Derived Xenografts, PDX）具有显著的治疗效果。为评估抗NOTCH1治疗的转录组下游效应，我们对经对照抗体（Ctrl Ab）或OMP-52M51急性处理后的、源自PDTALL46 PDX小鼠的白血病细胞开展了RNA测序（RNA-Seq）分析。我们收集了经对照抗体或OMP-52M51急性处理的小鼠脾脏细胞，用于RNA提取及RNA-Seq分析。所有样本均取自不同的小鼠，每组设置4只小鼠。